Alpha 2.0
Login Register
» Authors » Wolfgang Willenbacher

Wolfgang Willenbacher

Explore the profile of Wolfgang Willenbacher including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 79
Citations 1541
Followers 0
Related Specialties
Hematology
Oncology
General Medicine
Top 10 Co-Authors
Ella Willenbacher
Eberhard Gunsilius
Normann Steiner
Dominik Wolf
Richard Greil
Roman Weger
Andrea Brunner
David Nachbaur
Michael Mian
Andreas Petzer
Published In
Ann Hematol
Leuk Lymphoma
Cancers (Basel)
Int J Mol Sci
Am J Hematol
Affiliations
Soon will be listed here.
Recent Articles
1.
Beta-2-Microglobulin Maintains Overall Survival Prediction in Binet A Stage Chronic Lymphocytic Leukemia Patients with Compromised Kidney Function in Both Treatment Eras of Chemoimmunotherapy and Targeted Agents
Bohn J, Stolzlechner V, Gobel G, Willenbacher W, Pirklbauer M, Steiner N, et al.
Cancers (Basel) . 2024 Nov; 16(22). PMID: 39594701
: Elevated beta-2-microglobulin (B2M) plasma levels commonly imply a higher CLL-IPI risk category for short overall survival (OS), but the risk model was not adjusted for compromised kidney function and...
2.
QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 study
Ludwig H, Melchardt T, Schweitzer I, Sormann S, Schreder M, Andel J, et al.
EJHaem . 2024 Jun; 5(3):494-504. PMID: 38895059
Understanding the impact of induction and maintenance therapy on patients' quality of life (QoL) is important for treatment selection. This study aims to compare patient-reported QoL between patients treated with...
3.
Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies
Reimann P, Petzer V, Mundlein A, Hartmann B, Severgnini L, Winkler A, et al.
Ann Hematol . 2024 Mar; 103(6):2123-2131. PMID: 38436671
Monoclonal antibodies, as tixagevimab/cilgavimab, have been introduced as prophylaxis against COVID-19 infections in high-risk populations. However, data on efficacy are limited. This study investigates efficacy and tolerability of tixagevimab/cilgavimab in...
4.
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma
Ludwig H, Melchardt T, Sormann S, Schreder M, Andel J, Hartmann B, et al.
Am J Hematol . 2024 Mar; 99(5):1008-1011. PMID: 38425185
Randomized comparison between KTd and KRd induction followed by second randomization to carfilzomib in transplant-ineligable patients with newly diagnosed multiple myeloma.
5.
Abnormal biomarkers predict complex FAS or FADD defects missed by exome sequencing
Rensing-Ehl A, Lorenz M, Fuhrer M, Willenbacher W, Willenbacher E, Sopper S, et al.
J Allergy Clin Immunol . 2023 Nov; 153(1):297-308.e12. PMID: 37979702
Background: Elevated TCRαβCD4CD8 double-negative T cells (DNT) and serum biomarkers help identify FAS mutant patients with autoimmune lymphoproliferative syndrome (ALPS). However, in some patients with clinical features and biomarkers consistent...
6.
In-depth molecular analysis of lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis and rational treatment allocation
Brunner A, Thalhammer-Thurner G, Willenbacher W, Haun M, Zelger B, Willenbacher E
Ann Hematol . 2023 Nov; 103(2):553-563. PMID: 37951851
We performed a molecular analysis of formalin-fixed paraffin embedded and decalcified bone marrow trephine biopsies of 41 patients with a B-cell disorder with lymphoplasmacytic differentiation to enable a more precise...
7.
Adherence to Patient-Reported Symptom Monitoring and Subsequent Clinical Interventions for Patients With Multiple Myeloma in Outpatient Care: Longitudinal Observational Study
Lehmann J, de Ligt K, Tipelius S, Giesinger J, Sztankay M, Voigt S, et al.
J Med Internet Res . 2023 Aug; 25:e46017. PMID: 37606979
Background: The use of software to monitor patient-reported outcome measures (PROMs) can improve outcomes for patients with cancer receiving anticancer therapy; however, evidence from applications used in routine clinical practice...
8.
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study
Ansell S, Brockelmann P, von Keudell G, Lee H, Santoro A, Zinzani P, et al.
Blood Adv . 2023 Aug; 7(20):6266-6274. PMID: 37530622
Patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) for whom autologous hematopoietic cell transplantation (auto-HCT) had failed experienced frequent and durable responses to nivolumab in the phase 2 CheckMate 205...
9.
Attrition Rates in Multiple Myeloma Treatment under Real World Conditions-An Analysis from the Austrian Myeloma Registry (AMR)
Benda M, Ulmer H, Weger R, Reimann P, Lang T, Pichler P, et al.
Cancers (Basel) . 2023 Feb; 15(3). PMID: 36765918
Multiple myeloma (MM) is characterized by serial relapses, necessitating the application of sequential lines of therapy (LoT). Reports on attrition rates (ARs) vary widely. The present study analysed ARs from...
10.
Poor Mobilizers in Lymphoma but Not Myeloma Patients Had Significantly Poorer Progression-Free Survival after Autologous Stem Cell Transplantation: Results of a Large Retrospective, Single-Center Observational Study
Steiner N, Gobel G, Mauser L, Muhlnikel L, Fischinger M, Kunz T, et al.
Cancers (Basel) . 2023 Feb; 15(3). PMID: 36765566
In our single-center study, 357 myeloma and lymphoma patients between 2009 and 2019 were mobilized with granulocyte colony-stimulating factor (G-CSF 7.5 µg/kg bid for four days) plus a fixed dose...